EMEA-002559-PIP01-19
Key facts
| Active substance |
Anti-neonatal Fc receptor human monoclonal antibody
|
| Therapeutic area |
Other
|
| Decision number |
P/0288/2019
|
| PIP number |
EMEA-002559-PIP01-19
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Prevention of haemolytic disease of the foetus and newborn
|
| Route(s) of administration |
|
| Contact for public enquiries |
Janssen-Cilag International NV
Tel. +32 1460 2111 E-mail: contact@janssen-emea.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|